Status:
UNKNOWN
Using Mobile Devices for Neurofeedback to Reduce Opioid Use in Chronic Pain
Lead Sponsor:
CrossComm, Inc.
Collaborating Sponsors:
Duke University
National Institute on Drug Abuse (NIDA)
Conditions:
Chronic Pain
Opioid Use
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to develop and test the feasibility of a commercially-ready mobile neurofeedback app for individuals with chronic pain. Thirty (30) participants who are prescribed opioids...
Detailed Description
In this STTR Phase I project, CrossComm will collaborate with Duke University to develop a commercial-ready mobile neurofeedback technology and test its feasibility among patients using opioids to tre...
Eligibility Criteria
Inclusion
- Reports chronic pain (≥4 on 0-10 Numeric Rating Scale (NRS) on most days during the past 3 months)
- Prescribed opioids for pain management
Exclusion
- History of seizures
- Plans to have pain-related surgery in the next 3 months
- Has an implanted medical device that could experience interference during EEG, such as a spinal cord stimulator or pacemaker
Key Trial Info
Start Date :
June 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2024
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04838925
Start Date
June 22 2022
End Date
April 1 2024
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University School of Medicine Department of Psychiatry
Durham, North Carolina, United States, 27705